文献速递糖尿病

血清微小RNA与1型糖尿病高危亲属胰岛自身免疫、疾病进展及代谢损伤的关联

Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes.
PubMed 文献 · Diabetologia · 2017-05-12

该回顾性队列研究纳入TrialNet Pathway to Prevention研究中150例自身抗体阳性和150例自身抗体阴性的家庭匹配兄弟姐妹,检测93种血清微小RNA。部分微小RNA与胰岛自身免疫及1型糖尿病进展相关,其中miR-21-3p、miR-29a-3p和miR-424-5p关联最稳健,但ROC分析显示单一微小RNA诊断特异性与敏感性较低。

要点

  • 15种微小RNA在自身抗体阳性与阴性兄弟姐妹间差异表达,但ROC分析显示特异性与敏感性较低。
  • 7种微小RNA在自身抗体阳性亲属中按疾病进展差异表达,ROC曲线下面积显著。
  • miR-21-3p、miR-29a-3p和miR-424-5p与疾病进展关联最稳健。

核心结论

  • 部分血清微小RNA水平与年轻自身抗体阳性亲属的疾病进展相关,并增加1型糖尿病发病风险。
  • 需进一步研究(包括纵向评估)以明确微小RNA作为预测疾病风险和进展的生物标志物。

研究设计与样本

  • 回顾性队列研究,纳入TrialNet Pathway to Prevention研究中150例自身抗体阳性和150例自身抗体阴性的家庭匹配兄弟姐妹。
  • 检测93种血清中最常检出的微小RNA,分析其与自身抗体状态、未来糖尿病发生及OGTT C肽和血糖指标的关系。
  • 年轻队列(平均年龄11岁),多数自身抗体阳性亲属有多个自身抗体、处于高风险,39/150(26%,进展者)在平均8.7个月随访内发生1型糖尿病。

主要发现

  • 15种微小RNA在自身抗体阳性与阴性兄弟姐妹间差异表达(倍数变化范围-2.5至1.3),但ROC分析显示特异性与敏感性较低。
  • 7种额外微小RNA在自身抗体阳性亲属中按疾病进展差异表达,ROC曲线下面积显著,并确定与疾病风险增加相关的微小RNA临界值(横断面和生存分析均显著)。
  • 多种微小RNA水平与OGTT结局显著相关(r值范围0.22-0.55),其中miR-21-3p、miR-29a-3p和miR-424-5p关联最稳健。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出需进一步研究(包括纵向评估)以进一步明确微小RNA作为预测疾病风险和进展的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: MicroRNAs (miRNAs) are key regulators of gene expression and novel biomarkers for many diseases. We investigated the hypothesis that serum levels of some miRNAs would be associated with islet autoimmunity and/or progression to type 1 diabetes. METHODS: We measured levels of 93 miRNAs most commonly detected in serum. This retrospective cohort study included 150 autoantibody-positive and 150 autoantibody-negative family-matched siblings enrolled in the TrialNet Pathway to Prevention Study. This was a young cohort (mean age = 11 years), and most autoantibody-positive relatives were at high risk because they had multiple autoantibodies, with 39/150 (26%, progressors) developing type 1 diabetes within an average 8.7 months of follow-up. We analysed miRNA levels in relation to autoantibody status, future development of diabetes and OGTT C-peptide and glucose indices of disease progression. RESULTS: Fifteen miRNAs were differentially expressed when comparing autoantibody-positive/negative siblings (range -2.5 to 1.3-fold). But receiver operating characteristic (ROC) analysis indicated low specificity and sensitivity. Seven additional miRNAs were differentially expressed among autoantibody-positive relatives according to disease progression; ROC returned significant AUC values and identified miRNA cut-off levels associated with an increased risk of disease in both cross-sectional and survival analyses. Levels of several miRNAs showed significant correlations (r values range 0.22-0.55) with OGTT outcomes. miR-21-3p, miR-29a-3p and miR-424-5p had the most robust associations. CONCLUSIONS/INTERPRETATION: Serum levels of selected miRNAs are associated with disease progression and confer additional risk of the development of type 1 diabetes in young autoantibody-positive relatives. Further studies, including longitudinal assessments, are warranted to further define miRNA biomarkers for prediction of disease risk and progression.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Snowhite IV, Allende G, Sosenko J, et al. Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes. Diabetologia. 2017. PMID: 28500393. doi:10.1007/s00125-017-4294-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。